As the field of Clinical Genomics continues to yield new insights into diseases we are also shifting to a paradigm of phenotypic interpretation.
We have more access to health data than ever before with 80% of US hospitals adopting EHR systems and patient generated data growing exponentially. However it is disparate and often unstructured.
Heterogeneity of data of course poses challenges with many different types of data sets existing across many different platforms. We now have the tools to investigate the data in a more targeted way using Machine Learning algorithms.
We can now begin to extrapolate meaningful signals, revealing behaviours and patterns that can offer phenotypic insights.
How can these discoveries be used in early prediction of disease and thus early interventions across many different clinical settings, whether in primary care, the ICU or the NICU for example.
 Our San Diego breakfast briefing panel, which we are running in parallel with the annual ASHG conference will discuss some of the new opportunities for AI to support this endeavour and how a new generation of molecular tools will work in concert to help solve some of these challenges in interpretation.
They will also discuss issues that exist with data governance, structure, ownership and privacy within and indeed between institutions.
Furthermore how do we we bridge the knowledge gap between data science and medicine, given the exponential pace of development in this burgeoning area, so that clinicians are informed and satisfied that it will bring real value to patient care delivery.
Please join us in San Diego at the Marriott Marquis Harbor for what will be an engaging discussion with speakers representing Scripps, UCSD. and Sophia Genetics.
Sign up here
Topics on Clinical Genomics to be discussed will include:
  • Clinical genomics is just one of many modalities that will influence decision making in the clinic but it is only one element within a broader armamentarium of new molecular tools when used in concert will elucidate a more meaningful taxonomy of disease
  • At the provider level, how are AI systems being designed with the user in mind and how is the exponential pace of development becoming a critical issue for clinicians being informed about the real value to their practice.
  • How do we bridge the knowledge between data science and medicine, what is the bare minimum of knowledge a physician needs to know in order to converse in a meaningful way with a data scientist
  • How do we tackle issues around Data Structure/ Ownership and Privacy?
Speakers include:

Amalio Telenti, Chief Data Scientist, Director of the Genomics institute at Scripps Translational institute

Shumei Kato, MD, Assistant Clinical Professor, Experimental Therapeutics, GI Medical Oncology & Rare Tumor Clinic Division of Hematology & Oncology and Center for Personalized Cancer Therapy, UC San Diego Moores Cancer Center

Kevin Puylaert, Vice President of SOPHiA GENETICS’ North America

Sign up here